moneyheap
PHG · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Koninklijke Philips N.V. (PHG) stock moving?
Philips reported a Q3 2026 beat: adjusted EPS of $0.46 against $0.37 expected, sales of $5.055B against $4.990B, comparable sales up 3%, comparable order intake up 8%, adjusted EBITA margin up 70 basis points to 13.0%, and free cash flow of EUR 384M versus EUR 172M a year earlier. Full-year 2026 guidance was reiterated. Net income fell to EUR 28M from EUR 187M because of a EUR 288M provision for the Respironics agreement in principle with the U.S. DOJ, with payment expected in Q1 2027. The stock closed at 27.59 on Nov 2, gapped to 28.46 on Nov 3, then rose to 31.06 on Nov 4 on 3.0M shares, against a typical 1.2M to 1.4M. It peaked at 31.14 on Nov 5 and has since eased to 30.41 on Nov 10, with volume back to about 1.4M. Analysts followed with mostly higher targets: Barclays raised its target to EUR 33.50 with Overweight, Deutsche Bank to EUR 25 with Hold, and Bernstein raised its target while keeping Market Perform, so the ratings remain mixed. Product news (Azurion Butterfly in China, HyperVue in the U.S.) is incremental. The main offsets are the DOJ payment outflow and the reliance on the reiterated guidance being delivered.
News behind the analysis
- Koninklijke Philips Q3 Adj. EPS $0.46 Beats $0.37 Estimate, Sales $5.055B Beat $4.990B EstimatePhilips beat Q3 adjusted EPS and sales estimates, with adjusted EPS of $0.46 against $0.37 expected and sales of $5.055B against $4.990B.
- Philips Reiterates FY2026 Outlook: Comparable Sales Growth 3%-4.5%, Adjusted EBITA Margin 13.5%-14.0%, Free Cash Flow EUR 1.5B-1.7B, Including US Tariff Refund BenefitsPhilips kept its full-year 2026 guidance, including comparable sales growth of 3%-4.5%, an adjusted EBITA margin of 13.5%-14.0% and free cash flow of EUR 1.5B-1.7B.
- Philips Reports Strong Customer Demand, Improved ProfitabilityPhilips topped Q3 profit and revenue estimates on strong Connected Care sales and reaffirmed full-year guidance despite a EUR 288M DOJ settlement provision.
- Philips Q3 Free Cash Flow €384M vs €172M Y/YQ3 free cash flow rose to EUR 384M from EUR 172M a year earlier.
- Philips Q3 Adj. EBITA €569M, Margin 13.0%, Up 70 BpsAdjusted EBITA reached EUR 569M in Q3, a 13.0% margin, up 70 basis points year on year.
- Philips Says Respironics Reached Agreement In Principle With U.S. DOJ; Records €288M Provision, Payment Expected Q1 2027Respironics reached an agreement in principle with the U.S. DOJ, and Philips booked a EUR 288M provision with payment expected in Q1 2027.
- Barclays raises Philips price target to 33.50 EuroBarclays raised its Philips price target from EUR 29.50 to EUR 33.50 and kept an Overweight rating.
- Bernstein Increases Price Target for Koninklijke Philips N.V.Bernstein raised its price target on Philips while keeping a Market Perform rating.
- Deutsche Bank Research Adjusts Philips Price TargetDeutsche Bank Research raised its Philips price target from EUR 24 to EUR 25 and kept a Hold rating.
- Philips Launches Azurion Butterfly Image-Guided Therapy Platform in ChinaPhilips introduced its new-generation Azurion Butterfly image-guided therapy platform at the China International Import Expo.
About KONINKLIJKE PHILIPS N.V.
Royal Philips is a Dutch health technology company whose US-listed shares (ADRs) trade on the NYSE. Over the years it has dropped its lighting and appliance businesses to focus on hospital equipment such as imaging, image-guided therapy and patient monitoring, though it still sells well-known consumer brands like Sonicare, OneBlade and Avent.
How it makes money
Philips reports three segments. Diagnosis & Treatment is the largest, roughly 40-45% of sales, and covers MRI, CT, ultrasound and image-guided therapy systems. Connected Care, roughly 25-30%, covers hospital patient monitors, health informatics software and sleep and respiratory care. Personal Health, roughly 25%, sells electric toothbrushes, shavers, groomers and mother-and-child products. A meaningful share of revenue comes from service contracts on installed hospital equipment. Quarterly sales are about €4.4 billion (around €18 billion a year). In Q3 2026, sales grew about 3% on a comparable basis and the adjusted EBITA margin was about 13%.
What usually moves PHG
- Hospital equipment order intake and capital spending
- Respironics sleep-apnea device recall litigation and settlements
- Demand and competition in China
- US tariffs and euro-dollar exchange rates
- Margin and cost-saving progress